caus
agent
sar
identifi
novel
coronaviru
genom
sequenc
reveal
strong
homolog
exist
known
coronavirus
coronavirus
belong
famili
envelop
virus
call
coronavirida
largest
known
singlestrand
viral
rna
genom
kb
coronavirus
earli
late
phase
gene
express
regulatori
protein
synthes
earli
nonstructur
protein
structur
protein
synthes
late
protein
late
structur
protein
usual
requir
greater
amount
thu
necess
regul
express
viral
gene
quantit
viral
entri
via
endocytosi
specif
receptor
viral
genom
translat
directli
give
rise
twentythre
viral
protein
includ
rna
depend
rna
polymeras
rdrp
function
product
involv
transcript
replic
viral
assembl
cell
death
coronavirus
classifi
speci
three
major
antigen
group
base
serolog
natur
host
monoclon
antibodi
recognit
nucleotid
sequenc
coronavirus
restrict
host
rang
infect
one
host
speci
relat
speci
import
group
anim
pathogen
group
one
includ
human
coronaviru
hcov
porcin
transmiss
gastroenter
viru
tgev
felin
enter
coronaviru
fecov
group
two
ii
includ
bovin
coronaviru
bcov
murin
hepat
viru
mhv
group
three
iii
includ
avian
infecti
bronchiti
viru
ibv
coronavirus
like
hcov
restrict
tissu
tropism
includ
macrophag
although
strain
infect
human
caus
mild
respiratori
infect
howev
sar
rapidli
caus
worldwid
problem
earliest
known
case
sar
report
guandong
provinc
china
novemb
becom
widespread
march
introduc
canada
singapor
taiwan
vietnam
via
hong
kong
largest
number
infect
patient
china
worldwid
incid
total
juli
infect
viru
induc
high
morbid
mortal
latter
estim
world
health
organis
sar
character
high
fever
nonproduct
cough
dyspnea
mani
case
may
progress
gener
interstiti
infiltr
lung
thu
need
intub
mechan
ventil
characterist
compress
alveolar
sac
seen
atyp
pneumonia
larg
due
fluid
build
outsid
alveoli
one
possibl
caus
could
interstiti
inflamm
follow
localis
host
respons
date
detail
host
respons
sarscov
infect
still
larg
unknown
consequ
appropri
treatment
regim
remain
establish
typic
proinflammatori
cytokin
profil
regul
ifn
seen
viral
infect
influenza
togeth
perhap
limit
amount
chemokin
may
depend
cell
type
infect
experiment
system
immedi
innat
immun
respons
shown
direct
monocytemacrophagedendrit
lineag
rang
differ
organ
consist
core
set
pathway
common
togeth
pathogen
specif
pathway
data
point
critic
time
point
respons
first
hour
repres
primari
event
longer
period
consequ
activ
secondari
perhap
larger
cascad
respons
postul
pulmonari
damag
sar
may
direct
effect
viru
alveoli
repres
secondari
effect
cytokin
factor
proxim
lung
tissu
mediat
host
either
primari
secondari
respons
studi
address
question
develop
human
vitro
model
system
futur
allow
detail
investig
host
respons
made
pbmc
obtain
ficollhypaqu
separ
whole
blood
pbmc
seed
well
cultur
plate
ml
complet
life
technologiesinvitrogen
usa
ad
cultur
overnight
seed
stock
sarscov
strain
sin
passag
vero
cell
use
infect
vero
cultur
supernat
ad
well
volum
concentr
moi
base
plaqu
form
unit
control
plate
media
cultur
set
duplic
hour
incub
one
set
duplic
well
control
plate
hour
incub
plate
harvest
rest
receiv
ml
media
topup
incub
day
harvest
perform
gentli
flush
well
pasteur
pipett
remov
nonadher
cell
follow
rins
ml
rpmi
rins
fraction
pool
first
harvest
aliquot
spun
rpm
cell
pellet
wash
twice
ml
rpmi
remov
viru
supernat
ml
trizol
invitrogen
usa
ad
adher
cell
fraction
well
nonadher
cell
fraction
lyse
cell
stabil
rna
extract
total
rna
perform
follow
manufactur
protocol
result
rna
dissolv
water
amount
sarscov
cell
fraction
measur
realtim
quantit
pcr
assay
rna
revers
transcrib
amplifi
use
forward
revers
primer
mgb
probe
agagccatgcctaacat
nfq
one
step
pcr
use
master
mix
appli
biosystem
usa
accord
manufactur
recommend
reaction
perform
use
abi
prism
sequenc
detect
system
min
follow
min
cycl
sec
min
quantit
achiev
use
standard
curv
gener
vitro
transcrib
rna
time
point
hour
hour
hour
hour
cell
mockinfect
infect
cell
harvest
lyse
use
trizol
invitrogen
usa
total
rna
isol
accord
manufactur
recommend
qualiti
total
rna
judg
ratio
rna
agaros
gel
electrophoresi
total
rna
label
use
superscript
ii
reversetranscript
kit
invitrogen
usa
hybrid
carri
overnight
hour
highdens
oligonucleotid
array
gene
featur
compugen
use
univers
human
refer
stratagen
usa
refer
hybrid
array
scan
resolut
genepix
scanner
axon
instrument
variabl
photomultipli
tube
voltag
obtain
maxim
signal
intens
result
imag
analyz
via
genepix
pro
axon
instrument
describ
manual
raw
data
analyz
genepix
analysi
softwar
version
axon
instrument
upload
relat
databas
logarithm
express
ratio
spot
array
normal
subtract
median
logarithm
ratio
array
data
filter
exclud
spot
size
less
poor
qualiti
miss
spot
sinc
correl
overal
data
reciproc
label
good
valu
obtain
reciproc
label
experi
averag
addit
data
distil
set
gene
featur
present
time
point
viral
infect
sampl
neg
control
result
repres
logarithm
ratio
gene
express
viral
infect
sampl
correspond
neg
control
variou
time
point
applic
filter
result
inclus
total
gene
featur
subsequ
analys
discov
pattern
gene
express
valu
associ
gene
featur
f
translat
mean
zero
similar
gene
whose
translat
genefeatur
exhibit
inductionrepress
pattern
group
togeth
gene
gi
gj
said
similar
satisfi
follow
condit
u
x
x
u
x
otherwis
git
gjt
denot
translat
valu
gene
featur
gi
gj
time
respect
n
number
time
point
express
gene
observ
similar
gene
base
criteria
group
togeth
within
group
gene
order
descend
order
express
rang
defin
differ
maximum
minimum
ratio
gene
express
algorithm
special
case
friendli
neighbor
algorithm
current
develop
final
plot
gener
use
origin
express
ratio
preserv
cluster
order
discov
algorithm
determin
whether
gene
observ
respons
could
appear
mere
chanc
express
profil
gener
randomli
sampl
express
ratio
entir
dataset
replac
p
valu
gene
fraction
random
profil
whose
logarithm
express
rang
good
better
select
gene
obtain
pbmc
healthi
volunt
ficollhypaqu
separ
whole
blood
donor
pbmc
test
abl
support
sarscov
replic
infect
multipl
infect
moi
first
sampl
taken
cell
infect
hour
show
averag
copi
number
fig
repres
initi
inoculum
level
cours
next
day
steadi
rise
viral
load
reach
high
copi
per
well
one
donor
could
explain
activ
replic
sarscov
intracellularli
work
support
recent
vivo
evid
suggest
sarscov
may
infect
replic
within
pbmc
sar
patient
cell
human
anim
indic
pbmc
lineag
involv
provid
repeat
experi
use
monocytemacrophag
cell
line
viral
replic
similar
primari
cell
cultur
first
day
fig
primari
cultur
nonadher
cell
fraction
compris
mainli
lymphocyt
granulocyt
show
dramat
less
viral
replic
assay
cell
infect
moi
fig
kinet
viral
replic
variabl
among
donor
fig
lag
phase
day
case
donor
c
e
day
donor
b
f
signific
increas
could
detect
viral
replic
gener
peak
either
day
day
except
donor
b
viru
seem
replic
much
slower
pace
compar
donor
sampl
equal
interest
differ
level
viru
attain
donor
seem
stand
rest
reach
peak
copi
per
well
time
attain
donor
e
copi
per
well
variat
strongli
suggest
underli
hostpathogen
interact
influenc
kinet
sarscov
replic
effici
vitro
observ
may
reflect
wide
rang
patient
outcom
sarscov
infect
antibodi
block
experi
also
perform
sarscov
preincub
convalesc
patient
sera
minut
introduct
pbmc
day
incub
period
adher
cell
fraction
harvest
assay
sarscov
viral
titer
result
clearli
show
even
high
dilut
convalesc
sera
inhibit
sar
viral
replic
data
shown
presum
block
viral
entri
support
report
indic
sarscov
endocytos
antibodi
mediat
mechan
confirm
protect
role
antibodi
elicit
either
infect
immun
elucid
molecular
process
sarscov
infect
pbmc
healthi
individu
infect
separ
vitro
sarscov
moi
harvest
hour
hour
hour
hour
time
interv
postinfect
control
uninfect
aliquot
pbmc
also
harvest
correspond
time
point
total
rna
extract
pbmc
individu
pool
label
hybrid
human
oligonucleotid
array
consist
gene
featur
reciproc
dye
swap
replic
hybrid
perform
minim
technic
nois
analysi
varianc
express
level
gene
across
time
point
indic
gene
show
largest
variabl
fig
order
focu
analysi
queri
entir
data
set
gene
relat
immun
respons
keyword
search
gene
ontolog
descript
aim
describ
specif
hostpathogen
interact
common
studi
respiratori
pathogen
data
point
toward
two
critic
time
point
respons
first
hour
repres
primari
proinflammatori
cytokin
profil
longer
period
repres
consequ
activ
secondari
cascad
respons
observ
within
first
hour
sarscov
infect
evid
monocytemacrophag
activ
seen
indic
enhanc
express
plu
gata
signal
fig
tabl
addit
endocytot
receptor
upregul
complement
pathway
taken
togeth
data
suggest
earli
activ
innat
immun
pathway
activ
accompani
unusu
cytokin
transcript
profil
fig
tabl
regul
first
hour
would
expect
follow
macrophag
activ
note
surprisingli
low
level
express
spite
presenc
elev
thought
enhanc
regul
clinic
investig
concentr
tnf
il
measur
activ
diseas
found
rel
low
reflect
find
paper
report
ifn
level
howev
found
low
supplementari
figur
see
addit
file
particular
interest
ifn
shown
signific
antisarscov
effect
effect
suggest
alter
ifn
respons
perhap
immun
modul
might
provid
opportun
novel
treatment
manag
regim
sar
patient
develop
number
cc
chemokin
receptor
highli
express
respons
infect
fig
tabl
indic
rapid
mobil
increas
traffick
particular
monocytemacrophag
lineag
earli
infect
cxc
chemokin
also
highli
express
suggest
signific
increas
neutrophil
home
well
like
lung
direct
also
highli
express
specif
traffick
cell
lung
may
account
local
natur
respons
surprisingli
number
blood
coagul
gene
highli
express
earli
vitro
infect
fig
tabl
particular
tbxa
implic
vasoconstrict
platelet
aggreg
membran
lysi
increas
permeabl
fibrin
fgb
fgg
coagul
pathway
directli
serpin
togeth
factor
give
procoagul
profil
mimic
clinicalpatholog
observ
autopsi
mani
sar
patient
unusu
dissemin
small
vessel
thrombos
lung
without
evid
dissemin
intravascular
coagul
express
profil
provid
experiment
framework
explor
import
aspect
sar
pathobiolog
treatment
interest
note
highli
express
comparison
tlr
receptor
impli
degre
tlr
specif
viru
fig
known
respond
cpg
signal
motif
gtcgtt
one
possibl
viru
activ
directli
mechan
support
found
sarscov
viral
sequenc
contain
highest
number
copi
specif
signal
motif
compar
coronavirus
significantli
sever
virus
involv
respiratori
diseas
fig
conceiv
may
aid
host
recognit
viru
via
cpg
group
contribut
initi
innat
host
inflammatori
respons
altern
explan
stimul
mechan
unrel
cpg
recognit
emerg
pictur
studi
implic
central
role
immun
respons
pathobiolog
sar
infect
detail
vivo
studi
host
respons
requir
vitro
model
describ
allow
respons
specif
modul
therapeut
investig
futur
develop
model
interest
compar
host
respons
differ
sarscov
isol
inactiv
prepar
viru
diseas
vitro
model
reveal
number
key
process
relev
clinic
diseas
like
respons
identifi
prove
equal
import
although
clinic
paramet
use
prognost
marker
studi
regulatori
mechan
chemokinecytokin
product
like
improv
accuraci
perhap
allow
develop
new
treatment
protocol
none
declar
lfpn
mlh
etl
rec
conceiv
studi
design
coordin
result
analysi
draft
manuscript
eeo
kft
carri
viru
infect
syn
krkm
vnv
jmc
involv
array
statist
analysi
jt
carri
realtim
pcr
assay
prepubl
histori
paper
access
